MCTR3

MedChemE		Product Data Sheet	Inhibitors
MCTR3			•
Cat. No.: CAS No.:	HY-125516 1784701-63-8		Screening
Molecular Formula: Molecular Weight:	C ₂₅ H ₃₇ NO ₅ S 463.63		ng Libraries
Target: Pathway:	Others Others	летория он	ies •
Storage:	Please store the product under the recommended conditions in the Certificate Analysis.	e of	Proteins

BIOLOGICAL ACTI			
Description	MCTR3 is a potent cytok	ine of pro-resolving mediating maresin conjugates in tissue regeneration (MCTR), which reduces the and promotes the tissue regeneration. MCTR3 exhibits potency in ameliorating LPS-induced acute ^{[1][2][3]} .	
In Vitro	MCTR3 (1 nM) alleviates LPS-induced cellular damage and oxidative stress, reduces apoptosis and autophagy-related protein production in cells MLE12 through the ALX/PINK1 pathway ^[1] . MCTR3 (1 nM) enhances efferocytosis and bacterial phagocytosis by exudate leukocytes, reduces neutrophil infiltration and eicosanoids ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Immunofluorescence ^[1]		
	Cell Line:	MLE12	
	Concentration:	1 nM	
	Incubation Time:	24 h	
	Result:	Decreased LPS-stimulated expressions of PINK1 and Parkin.	
	Western Blot Analysis ^[1]		
	Cell Line:	MLE12	
	Concentration:	1 nM	
	Incubation Time:	24 h	
	Result:	Decreased levels of Bax, Bak, Cyto C and LC3BII/I, increased levels of BCL2 and Bcl-xl.	
In Vivo	decreases the apoptosis MCTR3 (1-100 nM, in colo with a 50% tissue regene	le dose) reduces inflammation and oxidative response in the LPS-induced acute lung injury and s in C57BL/6 mice ^[1] . d water) stimulates tissue regeneration in surgical injuried Planaria in a dose-dependent manner eration TRI ₅₀ of 2.5 days ^[2] . htly confirmed the accuracy of these methods. They are for reference only.	

® MedChemExpress

Animal Model:	Lipopolysaccharide induced acute lung injury in C57BL6 mice $^{[1]}$	
Dosage:	2 ng/g	
Administration:	i.p., single dose	
Result:	Reduced inflammatory cell infiltration and protein accumulation in bronchoalveolar lavage fluid (BALF), reduced MDA levels and increased SOD activity in lung tissue. Decreased levels of pro-inflammatory cytokine in serum.	
Animal Model:	Surgical injury in Planaria ^[2]	
Dosage:	1-100 nM	
Administration:	In cold water for 6 days	

REFERENCES

[1]. Zhuang R, et al., MCTR3 reduces LPS-induced acute lung injury in mice via the ALX/PINK1 signaling pathway. Int Immunopharmacol. 2021 Jan;90:107142.

[2]. Dalli J et al., Identification and Actions of a Novel Third Maresin Conjugate in Tissue Regeneration: MCTR3. PLoS One. 2016 Feb 16;11(2):e0149319.

[3]. Pistorius K, et al., MCTR3 reprograms arthritic monocytes to upregulate Arginase-1 and exert pro-resolving and tissue-protective functions in experimental arthritis. EBioMedicine. 2022 May;79:103974.

Caution: Product has not been fully validated for medical applications. For research use only.